LPTX
Leap Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−3.15%Year over year
Reported trailing growth
- Revenue
- -10.7%
- EBITDA
- +44.9%
- EBIT
- +58.5%
- EPS
- +104.4%
- Free cash flow
- -50.4%
- Operating cash flow
- -47.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +47.8%
- EBIT
- +47.8%
- Net income
- +107.1%
- EPS
- +104.0%
- Free cash flow
- +27.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025